Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial (Q88792022)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 May 2018

Language	Label	Description	Also known as
English	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial	scientific article published on 21 May 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Richard Russell

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Salman H Siddiqui

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Chris Brightling

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Charlotte Suppli Ulrik

7

object named as

Charlotte Suppli Ulrik

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Latifa Chachi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

J Mark FitzGerald

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Vibeke Backer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Ronald Olivenstein

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Ingrid L Titlestad

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Timothy Harrison

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Dave Singh

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Rekha Chaudhuri

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Brian Leaker

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lorcan McGarvey

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Millie Wang

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Martin Braddock

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lars H Nordenmark

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

David Cohen

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Himanshu Parikh

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Gene Colice

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

MESOS study investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

publication date

21 May 2018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

499-510

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

After asthma: redefining airways diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New and emerging drug treatments for severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lebrikizumab treatment in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum periostin in obstructive airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tezepelumab in Adults with Uncontrolled Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(18)30201-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29793857%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88792022&oldid=2235503482"